Komori
Immuno-Biological Laboratories (4570) · RiskWorsenedLatest General Meetings of Shareholders (2026-06-03): "Mitigated"

Risk of Tighter Regulation of Pharmaceuticals, Genetically Modified Organisms, Waste and Other Areas

First written in FY2016. 2 of 5 entries say "Restated". Latest entry: 2026-06-03.

5entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2019WorsenedFY20202016: 120162017: 120172018: 020182019: 120192020: 120202021: 020212022: 020222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Business constraints from tighter or changing regulations and litigation across multiple sectorsA theme 346 companies write about · 349 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2026: 22 of 71 companies on the "Worse" side.

10 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 350 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-06-03MitigatedGeneral Meetings of Shareholders

    「The Group is working to mitigate the impact of these risks by diversifying procurement sources, considering alternative resources, and optimizing logistics routes.」

    The Company identified diversification of procurement sources, alternative resources, and logistics-route optimization as measures to address the impact of the situation in the Middle East on raw-material prices, energy costs, and international logistics.
  2. FY2020WorsenedAnnual report

    「With respect to compliance with advanced regulations such as GMP, the business does not currently have sufficient facilities or know-how, and reducing manufacturing costs is an issue.」

    In addition to the general risk of tighter regulation, specifically identifies insufficient facilities and know-how for complying with advanced regulations such as GMP as issues.
  3. FY2019RestatedAnnual report

    「If regulations are tightened in the future through legal amendments or other measures, delays in research and development could have a material impact on operating results.」

    Restates the risks of tighter regulations concerning pharmaceuticals, genetically modified organisms, waste, and poisonous and deleterious substances.
  4. FY2017RestatedAnnual report

    「If regulations are tightened in the future through legal amendments or other measures, delays in research and development could have a material impact on operating results.」

    Restates the risks of tighter regulations concerning pharmaceuticals, genetically modified organisms, waste, poisonous and deleterious substances, and other matters.
  5. FY2016First statedAnnual report

    「If regulations are tightened in the future through legal amendments or other measures, delays in research and development could have a material impact on operating results.」

    Identifies tighter regulation under the Pharmaceutical Affairs Law, the Act on the Regulation of Manufacture and Evaluation of Genetically Modified Organisms, the Waste Management and Public Cleansing Act, and the Poisonous and Deleterious Substances Control Act as risks.
Moved together

"Expansion of Overseas Sales Activities" moved the same way as this thread, in the same document, in 2 of its 5 moves.

2222★1234
  1. ★This thread
  2. 1Expansion of Overseas Sales Activities2×
  3. 2Improving Profitability Through a Change in the Sales Policy for the Diagnostics and Reagents Business2×
  4. 3Securing Earnings and Focusing Management Resources2×
  5. 4Narrowing Operating Losses and Continued Losses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet. It last moved in the General Meetings of Shareholders of 2026-06-03: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Tighter Regulation of Pharmaceuticals, Genetically Modified Organisms, Waste and Other Areas | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori